
Avidicure Launches to Develop New Multifunctional Antibody Modality to Treat Cancer
Avidicure announced its launch with a $50 million seed financing round, led by EQT Life Sciences with participation from Kurma Partners, BioGeneration Ventures, BOM, Curie Capital, and V-Bio Ventures. Avidicure is developing dual agonistic, multifunctional …